 Connection
Parameswaran Venugopal to Antineoplastic Agents
This is a "connection" page, showing publications Parameswaran Venugopal has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.656 |
|
|
|
-
Larson ML, Venugopal P. Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jun; 10(8):1353-7.
Score: 0.297
-
Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
Score: 0.157
-
Shammo JM, Usha L, Richardson KJ, Elliott E, Dewdney S, Venugopal P, Cobleigh M, Kuzel TM. Olaparib-Induced Severe Folate Deficiency in a Patient With Advanced Ovarian Cancer. J Oncol Pract. 2019 07; 15(7):405-407.
Score: 0.149
-
Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|